Real-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)
This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer.
Related Guidelines in Practice articles
Dr Sonya Jey explains the importance of considering and excluding sinister causes of unintentional weight loss and explores some clinical scenarios in which unintentional weight loss is a feature
Professor Peter J Grant and Professor Francesco Cosentino highlight the key recommendations from the 2019 ESC/EASD guideline on diabetes, pre-diabetes, and CVD
Professor Alan Sinclair explains how care should be personalised and targets adapted for older people with diabetes, including an assessment of frailty
Muhammad Siddiqur Rahman highlights the integral role of practice-based pharmacists in managing type 2 diabetes
Dr Kevin Fernando describes eight common co-morbidities in patients with type 2 diabetes and how the co-existing conditions should be managed